Joanna Moore
University of Edinburgh
14 Papers
90 Citations
Joanna Moore is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Clinical trial & Medicine. The author has an hindex of 11, co-authored 14 publications. Previous affiliations of Joanna Moore include Royal Hallamshire Hospital.
Chat about Author
Papers
Safety profile of autologous macrophage therapy for liver cirrhosis.
Francesca Moroni,Benjamin J. Dwyer,Catriona Graham,Chloe Pass,Laura Bailey,Lisa Ritchie,Donna Mitchell,Alison Glover,Audrey Laurie,Stuart Doig,Emily Hargreaves,Alasdair R. Fraser,Marc Turner,John D.M. Campbell,Neil W. A. McGowan,Jacqueline Barry,Joanna Moore,Peter C. Hayes,Diana Julie Leeming,Mette Juul Nielsen,Kishwar Musa,Jonathan A. Fallowfield,Stuart J. Forbes +22 more
TL;DR: A first-in-human, phase 1 dose-escalation trial demonstrates the safety and feasibility of autologous macrophage therapy in adults with liver cirrhosis and provides a rationale for efficacy studies in cir rhosis and other fibrotic diseases.
Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial
Philip N. Newsome,Philip N. Newsome,Richard Fox,Richard Fox,Andrew King,Andrew King,Darren Barton,Darren Barton,Nwe-Ni Than,Nwe-Ni Than,Joanna Moore,Chris Corbett,Sarah Townsend,James Thomas,Kathy Guo,Kathy Guo,Diana Hull,Diana Hull,Heather A Beard,Jacqui Thompson,Anne P.M. Atkinson,Carol Bienek,Neil W. A. McGowan,Neil Guha,John D.M. Campbell,Dan Hollyman,Deborah Stocken,Christina Yap,Stuart J. Forbes +28 more
TL;DR: G-CSF with or without haemopoietic stem-cell infusion did not improve liver dysfunction or fibrosis and might be associated with increased frequency of adverse events compared with standard care.
143
Systematic review: the effects of autologous stem cell therapy for patients with liver disease
TL;DR: As morbidity and mortality from liver disease continues to rise, new strategies are necessary and autologous stem cell therapy has emerged as a potential treatment option.
68
Acute kidney injury in acute liver failure: a review
TL;DR: Improved understanding of the pathophysiology AKI in the context of acute liver failure may be beneficial in a number of areas, including the development of new and sensitive biomarkers of renal dysfunction, refining prognosis and organ allocation, and ultimately leading to the developed of novel treatment strategies.
66
Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis.
Alasdair R. Fraser,Chloe Pass,Paul Burgoyne,Anne P.M. Atkinson,Laura Bailey,Audrey Laurie,Neil W. A. McGowan,Akib Hamid,Joanna Moore,Benjamin J. Dwyer,Marc Turner,Marc Turner,Stuart J. Forbes,John D. M. Campbell,John D. M. Campbell +14 more
TL;DR: This is the first report of validation of a large-scale, fully Good Manufacturing Practice–compliant, autologous macrophage cell therapy product for the potential treatment of cirrhosis, and shows that the cell product in excipient is remarkably robust, consistently passing the viability and phenotypic release criteria up to 48 hours after harvest.
41